Dr. Claret will present two oncology case studies during a dedicated conference session on applications in model-based development:
-- June 18: A Modeling Framework to Simulate Xeloda Dose Intensity and Survival in Colorectal Cancer. Dr. Claret will present this case study as part of an oral conference session on the strategic use of modeling and simulation in oncology. The session will include applied examples of drug-disease modeling and will describe research on how quantitative, model-based approaches have been used to support dosing decisions of anticancer therapies in clinical practice. Rene Bruno, Ph.D., managing director, Pharsight Strategic Consulting Services, Europe, serves as conference chair for the oncology session. -- June 19: Modeling and Simulation to Assess the Use of Change in Tumor Size as Primary Endpoint in Phase II Studies in Oncology. Dr. Claret will present this case study in collaboration with Pharsight's client, a global pharmaceutical company, as part of a poster session on model-based applications in oncology. The session will describe research on a number of model-based approaches to support drug development in oncology, including tumor progression modeling and clinical trial simulations to predict efficacy and survival benefit of anticancer agents.
Dr. Claret and Dr. Bruno also contributed to a model-based analysis of tumor size measurements obtained in clinical oncology studies involving combination chemotherapy, as part of an ongoing collaboration between Pharsight and the University of Aix-Marseille School of Pharmacy. This analysis will be presented by Pharsight colleagues at the University of Aix-Marseille as part of the PAGE poster session on model-based applications in oncology.
"Model-based drug development continues to show value for enhancing
understanding of complex diseases in quantitative terms, and for improving the
confidence of drug development decisions," said
Additional information about PAGE can be found at http://www.page-meeting.org.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development
success: strong decision-making. By adopting the Pharsight approach, customers
acquire a new decision-making process with the potential to systematically
improve every level and phase of their business and scientific processes.
Pharsight Corporation is headquartered in
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations.
SOURCE Pharsight Corporation